Tumor size exceeding 5 cm as a valid prognostic factor in all stages of thymic epithelial tumors
Purpose This study investigated the prognostic factors of thymic epithelial tumors (TETs) to identify patients who require multidisciplinary treatment and improve the TET prognosis. Methods We retrospectively reviewed the data of 268 TET patients. Prognostic variables for the overall survival (OS) were analyzed in all TET stages (n = 268), and the recurrence-free survival (RFS) was analyzed in patients who achieved complete resection (n = 164). Results The median follow-up period was 7 years; thymic carcinomas (TCs) and advanced stages of tumor, node, and metastasis (TNM) classification had the worse prognosis according to a Kaplan–Meier analysis. The cut-off value of the tumor size to predict the OS and RFS was determined using modified Harrell’s c-index calculated by a Cox regression analysis of the OS. Regarding the OS, a multivariate analysis revealed that age > 70 years old (p = 0.011), tumor size > 5 cm (p < 0.001), and TCs (p = 0.002) were significant prognostic factors aside from the TNM stage (p < 0.001). Regarding the RFS, tumor size > 5 cm was the only significant prognostic factor in the multivariate analysis (p = 0.002) aside from the TNM stage (p = 0.008). Conclusions Tumor size > 5 cm was shown to be a prognostic predictor in addition to the WHO and TNM classifications. Therefore, multidisciplinary treatment should be developed for TET patients with poor prognostic factors, specifically tumor size..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Surgery today - 53(2022), 1 vom: 30. Juli, Seite 42-50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sakai, Takashi [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. 2022. corrected publication 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00595-022-02530-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2080247247 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2080247247 | ||
| 003 | DE-627 | ||
| 005 | 20230507085717.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00595-022-02530-7 |2 doi | |
| 035 | |a (DE-627)OLC2080247247 | ||
| 035 | |a (DE-He213)s00595-022-02530-7-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Sakai, Takashi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor size exceeding 5 cm as a valid prognostic factor in all stages of thymic epithelial tumors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. 2022. corrected publication 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose This study investigated the prognostic factors of thymic epithelial tumors (TETs) to identify patients who require multidisciplinary treatment and improve the TET prognosis. Methods We retrospectively reviewed the data of 268 TET patients. Prognostic variables for the overall survival (OS) were analyzed in all TET stages (n = 268), and the recurrence-free survival (RFS) was analyzed in patients who achieved complete resection (n = 164). Results The median follow-up period was 7 years; thymic carcinomas (TCs) and advanced stages of tumor, node, and metastasis (TNM) classification had the worse prognosis according to a Kaplan–Meier analysis. The cut-off value of the tumor size to predict the OS and RFS was determined using modified Harrell’s c-index calculated by a Cox regression analysis of the OS. Regarding the OS, a multivariate analysis revealed that age > 70 years old (p = 0.011), tumor size > 5 cm (p < 0.001), and TCs (p = 0.002) were significant prognostic factors aside from the TNM stage (p < 0.001). Regarding the RFS, tumor size > 5 cm was the only significant prognostic factor in the multivariate analysis (p = 0.002) aside from the TNM stage (p = 0.008). Conclusions Tumor size > 5 cm was shown to be a prognostic predictor in addition to the WHO and TNM classifications. Therefore, multidisciplinary treatment should be developed for TET patients with poor prognostic factors, specifically tumor size. | ||
| 650 | 4 | |a Thymic epithelial tumors | |
| 650 | 4 | |a Prognostic factors | |
| 650 | 4 | |a Tumor size | |
| 700 | 1 | |a Aokage, Keiju |0 (orcid)0000-0003-3193-9646 |4 aut | |
| 700 | 1 | |a Miyoshi, Tomohiro |4 aut | |
| 700 | 1 | |a Tane, Kenta |4 aut | |
| 700 | 1 | |a Ishii, Genichiro |4 aut | |
| 700 | 1 | |a Goto, Koichi |4 aut | |
| 700 | 1 | |a Tsuboi, Masahiro |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgery today |d Springer Nature Singapore, 1992 |g 53(2022), 1 vom: 30. Juli, Seite 42-50 |w (DE-627)170846210 |w (DE-600)1115435-4 |w (DE-576)03273302X |x 0941-1291 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2022 |g number:1 |g day:30 |g month:07 |g pages:42-50 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00595-022-02530-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2018 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 53 |j 2022 |e 1 |b 30 |c 07 |h 42-50 | ||